Shares of Genomic Health, Inc. (NASDAQ:GHDX) have earned a consensus rating of “Hold” from the ten analysts that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $31.83.

A number of brokerages have recently commented on GHDX. Jefferies Group LLC reissued a “hold” rating and set a $33.00 price objective on shares of Genomic Health in a report on Thursday, September 14th. Cowen and Company reissued a “hold” rating and set a $34.00 price objective on shares of Genomic Health in a report on Friday, September 1st. BidaskClub raised Genomic Health from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Canaccord Genuity lowered their price objective on Genomic Health from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, August 15th. Finally, Piper Jaffray Companies reissued a “hold” rating and set a $31.00 price objective on shares of Genomic Health in a report on Thursday, August 3rd.

Genomic Health (NASDAQ:GHDX) opened at 31.14 on Wednesday. Genomic Health has a 52 week low of $26.37 and a 52 week high of $33.97. The stock has a 50 day moving average of $30.86 and a 200 day moving average of $31.62. The company’s market cap is $1.08 billion.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.02). The company had revenue of $85.50 million for the quarter, compared to analyst estimates of $86.08 million. Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The business’s revenue was up 4.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.18) EPS. On average, analysts expect that Genomic Health will post ($0.01) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first reported by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/20/genomic-health-inc-ghdx-given-consensus-rating-of-hold-by-analysts.html.

In related news, CEO Kimberly J. Popovits sold 1,468 shares of the stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $32.67, for a total transaction of $47,959.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Steven Shak sold 5,000 shares of the stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $33.27, for a total value of $166,350.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,642 shares of company stock valued at $1,509,431. 46.20% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in GHDX. Dubuque Bank & Trust Co. boosted its stake in Genomic Health by 8.4% during the 2nd quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock valued at $159,000 after purchasing an additional 379 shares during the period. Legal & General Group Plc boosted its stake in Genomic Health by 48.7% during the 1st quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 2,038 shares during the period. SG Americas Securities LLC boosted its stake in Genomic Health by 37.8% during the 2nd quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock valued at $199,000 after purchasing an additional 1,679 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Genomic Health during the 1st quarter valued at approximately $218,000. Finally, Envestnet Asset Management Inc. boosted its stake in Genomic Health by 13.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 8,282 shares of the medical research company’s stock valued at $259,000 after purchasing an additional 993 shares during the period. Hedge funds and other institutional investors own 88.90% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.